The drug Avastin should lose its approval for treatment of advanced breast cancer because there is no evidence that it benefits patients, U.S. Food and Drug Administration staff said Tuesday on the first day of a two-day FDA hearing.
But about a dozen breast cancer patients urged the agency to change its mind about a decision made last December to revoke Avastin's approval for advanced breast cancer. The hearing is being held to give drug maker Genentech one last chance to convince the FDA to reverse that decision, The New York Times reported.
|